TNFRSF9 and Miyoshi myopathy: A clinical trial evaluating a dual-target BM38 CAR incorporating both anti-CD38 and anti-BCMA single-chain variable fragment in tandem plus 4-1BB (CD137) signaling and CD3 zeta domains for relapsed and/or refractory MM is currently ongoing in China [218].